Steriwave in first Australian hospital

Ondine Biomedical Inc.
22 April 2024
 

Non-regulatory announcement

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Steriwave in first Australian hospital

Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical's award-winning light-activated antimicrobial technology

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.

Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients."

Orthopaedic Spine Surgeon Dr John Street, Director of the Integrated Ambulatory Spine Program at Vancouver Coastal Health and upcoming President of the Canadian Spine Society, was a keynote speaker at the recent 2024 Spine Society of Australia 35th Annual Scientific Meeting that was held in Sydney on April 5-7th, 2024. Dr Street presented the results of his team's 14-year study evaluating Steriwave's effect on SSIs following spine surgery at Vancouver General Hospital ("VGH"), concluding that Steriwave nasal photodisinfection should be part of routine use and recommended it as standard of care for all elective and emergent spine surgeries.

The VGH research involved 13,493 patients and demonstrated a 66.5% reduction (7.98% vs 2.67%, p<0.001) in surgical site infections (SSIs) following spine surgery when Ondine's Steriwave nasal photodisinfection (nPDT) was implemented in the universal pre-surgical infection prevention protocol. The researchers also found average net annual cost saving of $2.49 million, a saving of over $2,400 per spine surgery patient, post rollout.

**ENDS**

Enquiries:

Ondine Biomedical Inc.       

 

Carolyn Cross, CEO 

+001 (604) 665 0555

 

 

Singer Capital Markets
(Nominated Adviser and Joint Broker)

 

Aubrey Powell, Sam Butcher

+44 (0)20 7496 3000

 

 

RBC Capital Markets (Joint Broker)

 

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000


 

Vane Percy & Roberts (Media Contact)


Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and many other indications.

About Steriwave®

Ondine's Steriwave® nasal photodisinfection system is a patented technology using a proprietary light-activated antimicrobial (photosensitizer) to destroy bacteria, viruses, and fungi colonizing the nose. The photodisinfection treatment is carried out by a trained healthcare professional and is an easy to use, painless, two-step process. The photosensitizer is applied to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of red laser light for less than five minutes. The light activates the photosensitizer, causing an oxidative burst that is lethal to all types of pathogens without causing long-term adverse effects on the nasal microbiome. A key benefit of this approach-unlike with antibiotics, which have resistance rates reported as high as 81%[1]-is that pathogens do not develop resistance to the therapy.

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[2] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[3]

 



[1] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

[2] https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

[3] Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings